Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009:2009:681482.
doi: 10.1155/2009/681482. Epub 2009 Dec 13.

Mizoribine: a new approach in the treatment of renal disease

Yukihiko Kawasaki  1
Affiliations
Review

Mizoribine: a new approach in the treatment of renal disease

Yukihiko Kawasaki. Clin Dev Immunol. 2009.

Abstract

Mizoribine (MZB) is an imidazole nucleoside and an immunosuppressive agent. The immunosuppressive effect of MZB has been reported to be due to the inhibition of DNA synthesis in the S phase of the cell cycle. Because of its relative lack of toxicity, during the past decade MZB has been frequently used instead of azathioprine as a component of immunosuppressive drug regimens. MZB is being used to treat renal transplantation patients, IgA nephropathy, lupus erythematosus, and childhood nephrotic syndrome (NS), and some recent studies have assessed the efficacy of oral MZB pulse therapy for severe lupus nephritis, steroid-resistant NS, and frequently relapsing-steroid-dependent NS. This review summarizes the published findings on the efficacy of MZB for renal disease including IgA nephropathy, lupus nephritis, and NS, as well as of oral MZB pulse therapy for severe lupus nephritis and NS, and also the mechanism of the effect of oral MZB pulse therapy on the lymphocyte cell cycle.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in the serum MZB concentration of each patient on the days when MZB was administered.
See this image and copyright information in PMC

References

    1. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K. Studies on bredinin. I. Isolation, characterization and biological properties. Journal of Antibiotics. 1974;27(10):775–782. - PubMed
    1. Kamata K, Okubo M, Ishigamori E, et al. Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplantation. 1983;35(2):144–149. - PubMed
    1. Ichikawa Y, Ihara H, Takahara S. The immunosuppressive mode of action of mizoribine. Transplantation. 1984;38(3):262–267. - PubMed
    1. Ishikawa H. Mizoribine and mycophenolate mofetil. Current Medicinal Chemistry. 1999;6(7):575–597. - PubMed
    1. Hamasaki T, Mori M, Kinoshita Y, Saeki T, Sakano T. Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatric Nephrology. 1997;11(5):625–627. - PubMed

MeSH terms